NBSE — NeuBase Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for NeuBase Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 3 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-Q |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27 | -17.4 | -25.4 | -33.8 | -4.37 |
| Depreciation | |||||
| Non-Cash Items | 23.4 | 5.91 | 5.77 | 3.82 | -0.323 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.623 | 0.479 | 0.361 | 0.177 | -1.19 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -2.85 | -10.7 | -18.9 | -29 | -5.69 |
| Capital Expenditures | -0.509 | -0.717 | -1.44 | -0.472 | -0.05 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.176 | 0 | -1.13 | -0 | 0 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.685 | -0.717 | -2.56 | -0.472 | -0.05 |
| Financing Cash Flow Items | -0.09 | -0.35 | -0.382 | -0.148 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 13.6 | 33.1 | 42.3 | -0.257 | -0.029 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 10.1 | 21.7 | 20.9 | -29.7 | -5.77 |